Navigation Links
Heartburn Drugs May Contribute to the Problem
Date:7/7/2009

Study suggests proton pump inhibitors could aggravate acid trouble

TUESDAY, July 7 (HealthDay News) -- Drugs commonly used to treat heartburn and acid reflux may actually cause heartburn.

A new study in the July issue of Gastroenterology found that treatment with a proton pump inhibitor (PPI) actually produced heartburn, acid reflux and indigestion in healthy volunteers who took the medication for eight weeks.

Although the findings don't necessarily mean that PPIs don't have a valid place in the gastrointestinal armamentarium, they do strongly suggest that overprescribing may be causing harm, the study authors said.

"It is beyond any doubt that subjects with reflux disease benefit from and need treatment with acid suppressive drugs," said study lead author Dr. Cristina Reimer of Copenhagen University in Denmark. "But it is equally beyond doubt that PPIs are prescribed more or less uncritically for a wide variety of symptoms where the initial effect of the drug is doubtful.

"The findings in our study [indicate that] this liberal prescribing is likely to create the disease the drugs are designed to treat," she continued. "Patients who are treated on uncertain indication thus risk developing a true need for continued therapy. Our findings challenge the very liberal prescribing of these drugs, and this study should lead to careful consideration about possible changes in prescribing habits."

According to an accompanying editorial in the journal, about 5 percent of the developed world's population now uses PPIs.

And more people are using the drugs long-term, although this should only occur when a person has severe gastroesophageal reflux disease (GERD) or to prevent problems in people taking nonsteroidal anti-inflammatory medications, such as aspirin, which can be hard on the stomach, the researchers said.

But according to the study authors, about one-third of patients who take PPIs renew their prescriptions without one of these indications. And the editorial stated that the drugs are being prescribed without hard evidence that acid is involved with the problem. PPIs work by reducing acid production.

For this study, 120 healthy people were randomly assigned to receive 12 weeks of a placebo or eight weeks of Nexium (esomeprazole, 40 milligrams a day), followed by four weeks of placebo.

Forty-four percent of individuals receiving the PPI reported acid-related symptoms afterstopping the medication, compared with 15 percent in the placebo group.

The study authors speculated that the post-treatment effect comes from an acid "rebound" after the period of inhibition. If this does turn out to be the case, the process could end up causing dependency on PPIs, the researchers said.

"Patients need to be informed about the potential effects of the rebound acid hypersecretion and the symptoms it can cause when therapy is initiated," said Reimer, adding that more research into the phenomenon is needed.

"If both patients and their physicians are aware of this temporary period of time after discontinuation [that might include] aggravation or induction of acid-related symptoms, it is possible that withdrawal of therapy is easier to achieve," she added.

Blair Hains, a spokesman for AstraZeneca, which makes Nexium, said: "This study was conducted with healthy volunteers, and the authors acknowledge that they can't be sure that the conclusion can be carried over to patients who have started PPI therapy because of dyspeptic symptoms. A previous systematic review of rebound acid hypersecretion after discontinuation of PPIs concludes that there is no strong evidence for a clinically relevant increased acid production after withdrawal of PPI therapy."

More information

Visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases for more on GERD.



SOURCES: Christina Reimer, M.D., department of medical gastroenterology, Koge University Hospital, Copenhagen University, Denmark; Blair Hains, spokesman, AstraZeneca; July 2009, Gastroenterology


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Heartburn Can Be a Sign of Serious Disease
2. Survey Reveals Heartburn Sufferers Experience More Heartburn During the Holidays
3. FDA Confirms No Heart Risk From Heartburn Drugs
4. AUDIO from Medialink and Prilosec OTC: Recipes for Heartburn-Friendly Super Bowl Snacking
5. First Over-The-Counter Store Brand Omeprazole Offering in U.S. Market Creates New Option for Frequent Heartburn Sufferers
6. Survey Reveals Heartburn Sufferers Experience More Heartburn During the Holidays
7. CHPA, Nielsen: OTC Heartburn Therapy Saves Nearly $800 Million Annually, Vast Majority of OTC Heartburn Consumers Satisfied
8. Plavix Plus Heartburn Drugs May Hike Heart Risk
9. Blood Thinner, Heartburn Drugs May Be Risky After Heart Attack
10. Heartburn Sufferers Find Lasting Relief With TUMS(R) Dual Action
11. Heartburn medications do not ease asthma symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide for ... as an education tool in the war against teen drug abuse. NCADD is ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... 10.2 version gives development continuity to its innovative Unified Instance Manager architecture, ... capacity. In addition, this new version optimizes the unattended auto-dialing system without ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: